The U.S. over the counter (OTC) drugs market was valued at US$ 41.93 billion in 2024 and is projected to reach a market valuation of US$ 69.65 billion by 2033, growing at a CAGR of 5.8% during the ...

Samsung Bioepis Co. and Celltrion Inc. are outpacing long-established global drug manufacturers such as Amgen Inc. and Sandoz ...

The World Health Organization says it will send leprosy drugs to Nigeria this weekend after resolving testing hold-ups that ...

Collaborators are listed at the end of the paper.

The US shift toward steep tariffs will likely make drugs more expensive and limit access for patients, according to one of ...

The FDA has approved two new biosimilars of denosumab for all indications of the reference medications Prolia and Xgeva, ...

The FDA had approved Otulfi in September 2024 to treat Crohn’s disease, ulcerative colitis, psoriasis and active psoriatic arthritis. Information on pricing is not yet available.

Supplied. In the pharmaceutical industry regulatory hurdles often derail ambitions. But a Melbourne-based Avecho Biotechnology has turned regulation to its advantage, signing a deal with ₣17 billion ...

So, sales of Pluvicto, a medication for the treatment of prostate ... its revenue continued to grow steadily after the spin-off of Sandoz (OTCQX:SDZNY), which was completed in early October ...

(Bloomberg) -- Novartis AG’s Sandoz family is poised to sell a roughly 1.2% stake in the Swiss pharmaceutical group. The Sandoz Family Foundation, through the vehicle Emasan AG, is offering 26.5 ...

ZURICH, Feb 26 (Reuters) - The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling a chunk of Swiss pharma giant Novartis (NOVN.S), opens new tab ...

Samsung Bioepis launched this product, under the brand name Pyzchiva, in the US earlier this week with partner Sandoz. Despite the contract not permitting Samsung to sub-license its rights for an ...